Navigation Links
PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008

ANNAPOLIS, Md., Sept. 18 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company will present two poster presentations and an oral presentation on its Protexia(R) and Valortim(R) medical countermeasures programs at the upcoming HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Stakeholders Workshop 2008 / BARDA Industry Day, being held in Alexandria, VA September 24 -26, 2008.

Protexia(R), a recombinant version of human butyrylcholinesterase (BChE), is being developed as a pre- and post-exposure therapy for casualties on the battlefield or civilian victims of nerve agent attacks. Valortim(R), in co-development with Medarex, Inc., is a fully human monoclonal antibody designed to treat and protect against inhalational anthrax.

The HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Stakeholders Workshop 2008 and BARDA Industry Day will bring together public and private sector stakeholders for a dynamic dialogue on the current state of medical countermeasure preparedness, PHEMCE initiatives in the past year, and plans for moving forward to enhance national capabilities to respond to a public health emergency.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:
-- SparVax(TM) - a second generation recombinant protective antigen (rPA)

anthrax vaccine

-- Third generation rPA anthrax vaccine

-- Valortim(R) - a fully human monoclonal antibody for the prevention and

treatment of anthrax infection

-- Protexia(R) - a novel bioscavenger for the prevention and treatment of

morbidity and mortality associated with exposure to chemical nerve


-- RypVax(TM) - a recombinant dual antigen vaccine for plague

For more information about PharmAthene, please visit

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PharmAthene to Present at the UBS Global Life Sciences Conference on Thursday September 25, 2008
2. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
3. PharmAthene Reports Second Quarter 2008 Financial and Operational Results
4. Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene
5. PharmAthene Appoints Jordan P. Karp, J.D. Senior Vice President and General Counsel
6. PharmAthene Reports First Quarter 2008 Financial Results
7. PharmAthene to Host First Quarter 2008 Conference Call and Webcast on Tuesday, May 13, 2008
8. PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
9. PharmAthene Reports Year-End 2007 Financial Results
10. Department of Defense Awards $5.8 Million Contract Modification Providing Additional Funding for PharmAthenes Protexia(R) Program
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... BioMarketing, a leading provider of patient support solutions, has announced ... network, which will launch this week. The VMS CNEs will ... to enhance the patient care experience by delivering peer-to-peer education ... professionals to help women who have been diagnosed and are ... ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... , ... October 10, 2017 , ... Dr. Bob Harman, ... his local San Diego Rotary Club. The event entitled “Stem Cells ... and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human ...
Breaking Biology Technology:
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
(Date:3/28/2017)... The report "Video Surveillance Market ... Storage Devices), Software (Video Analytics, VMS), and Service (VSaaS, ... to 2022", published by MarketsandMarkets, the market was valued ... to reach USD 75.64 Billion by 2022, at a ... year considered for the study is 2016 and the ...
Breaking Biology News(10 mins):